Loading
A phase 2 trial of ipilimumab and nivolumab in lung cancer, run by Brown University, now recruiting.
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab is a phase 2, interventional study registered as NCT04933903 by Brown University, with a registry enrolment figure of 25 participants, started 2021-10-05 and due to reach its primary completion in 2026-10. Interventions recorded: Ipilimumab; Nivolumab; SBRT. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Number of Patients with a Pathologic Response. Lung eligibility wording from the registry: "Pathologically confirmed NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/